Study on Depleting Alpha/Beta T Cells and CD19+ B Cells in Stem Cell Transplants for Patients with Blood Cancers

Inclusion Criteria

• Children, adolescents, and young adults (ages 6 months to 39 years) with specific blood cancers, including:
  • Acute Lymphocytic Leukemia (ALL) with high-risk features or in second remission and beyond.
  • Acute Myeloid Leukemia (AML) with certain genetic markers, in remission, or with minimal residual disease.
  • Juvenile Myelomonocytic Leukemia (JMML) in remission or with recurrence.
  • Chronic Myeloid Leukemia (CML) in remission.
  • High-risk Myelodysplastic Syndrome (MDS).
  • Hodgkin or Non-Hodgkin Lymphoma with a history of treatment failure or in partial or complete remission.
• Must not have more than one active cancer at the time of joining the study.
• Must have a suitable donor for stem cell donation, either a matched sibling, unrelated donor, or a partially matched related donor.
• Must have a performance status score of 60% or higher, indicating the ability to carry out daily activities.
• Must have adequate organ function, including lungs, kidneys, heart, and liver, as determined by specific medical tests.
• Must provide written informed consent and agree to follow all study procedures.
• Participants of childbearing potential must use effective contraception during the study and for 8 weeks after the last treatment.

Exclusion Criteria

• Patients with uncontrolled infections.
• Patients who have had a stem cell transplant in the last 6 months, unless it's a boost.
• Patients with active moderate to severe graft-versus-host disease (GVHD).
• Patients who have not followed medical care instructions in the past.
• Individuals who are unwilling or unable to use contraception during the study and for 8 weeks after.
• Pregnant or breastfeeding women.
• Individuals with other medical conditions that could interfere with the study or increase the risk of complications.
• Prisoners or individuals who are detained for treatment of psychiatric or physical illnesses.